Welcome to our dedicated page for Zhongchao news (Ticker: ZCMD), a resource for investors and traders seeking the latest updates and insights on Zhongchao stock.
Zhongchao Inc. (NASDAQ: ZCMD) is a Cayman Islands holding company whose PRC operating entities are described as a platform-based internet technology business focused on patients with oncology and other major diseases, as well as online medical education. The ZCMD news feed highlights how the company’s activities in China intersect with cancer care, chronic disease management, health education, and capital markets disclosures.
News about Zhongchao frequently covers patient management and medication assistance projects. Company announcements describe initiatives for breast cancer patients, lung cancer patients, and individuals with systemic lupus erythematosus, including disease management services, patient-reported outcome-based models, and free medication programs for low-income patients. These projects often involve collaborations with hospitals, pharmacies, pharmaceutical enterprises, non-profit organizations, and public health foundations.
Another recurring theme in Zhongchao’s news is its role in professional and public health education. Releases describe the MDMOOC platform for healthcare professionals, the Digital Online Education Platform for Common Diseases Clinical Diagnosis and Treatment, and partnerships with the Ximalaya audio platform to deliver cancer education series such as “Let’s Talk About Tumors.” These items illustrate how the company uses digital channels to share medical knowledge with both clinicians and the general public.
Investors following ZCMD news will also see updates on pharmaceutical services and capital market actions, including the integration of Naiditawei® (Oseltamivir Phosphate Capsules) into listed online procurement programs in multiple Chinese regions, and corporate actions such as a 1-for-10 share consolidation aimed at maintaining Nasdaq Capital Market listing compliance. For ongoing developments in these areas, the Zhongchao news page aggregates company press releases and related coverage in one place.
Zhongchao Inc. (NASDAQ: ZCMD) has launched its "Surgical-Interventional-Drug" (SID) platform aimed at enhancing liver cancer physician education in response to rising cases in China, where around 400,000 new liver cancer cases were reported in 2020. Designed to support comprehensive management and treatment strategies, the SID Platform has been accessed approximately 290,000 times by physicians. This initiative aligns with the National Health Commission's treatment guidelines and aims to improve ongoing professional development for healthcare providers, ultimately benefiting liver cancer patients.
Zhongchao Inc. (NASDAQ: ZCMD) announced that its operational entity, Chongqing Xinjiang Pharmaceutical Co., Ltd., has secured multiple pharmaceutical licenses, paving the way for expansion into the pharmaceutical market. These include a Pharmaceutical Trade License and a Medical Device Trade License. The company aims to enhance its 'Medical-Pharmaceutical-Patient' model, addressing oncology and major diseases. With an eye on strengthening its market presence, Xinjiang Pharmaceutical will engage in drug import/export and online pharmaceutical services, supported by extensive partnerships and educational resources.
Zhongchao Inc. (NASDAQ: ZCMD) announced the establishment of Chongqing Xinjiang Pharmaceutical Co., Ltd. to enhance the accessibility and affordability of medications for patients with oncology and other major diseases. This new entity aims to streamline pharmaceutical procurement via a 2B2C platform, collaborating with Zhixun Internet Hospital and others. The initiative is part of Zhongchao's strategy to expand its 'Medical-Pharmaceutical-Patient' model, addressing growing patient-oriented healthcare demands in China. The company seeks to improve drug delivery and patient experience.
Zhongchao Inc. (NASDAQ: ZCMD) announced the launch of its subsidiary Zhixun Internet Hospital in Liaoning, aimed at providing standardized Internet healthcare services for oncology and major diseases. This initiative enhances Zhongchao's patient management capabilities by offering comprehensive services, including remote consultations and follow-up visit management. The All-in-One Service model aims to improve treatment continuity and patient outcomes. Chairman Weiguang Yang emphasized the importance of connecting in-hospital and out-of-hospital services to enhance the quality of medical care.
Zhongchao Inc. (NASDAQ: ZCMD) has announced a strategic shift to expand its business model from 'Medical-Pharmaceutical' to 'Medical-Pharmaceutical-Patient', focusing on oncology and major disease management. The company launched its patient management business in 2021, achieving a 40.4% improvement in Duration of Therapy for liver cancer patients using its self-developed system. Over hundreds of thousands of patients have benefited from disease management services. CEO Weiguang Yang emphasized the commitment to digital innovation in healthcare to enhance patient outcomes and drive shareholder value.
Zhongchao Inc. (NASDAQ: ZCMD) announced the launch of its MDMOOC platform's online training course titled "Disease Prevention and Distribution Quality Management," aimed at enhancing skills in vaccination management for up to 20,000 healthcare staff. The course, launched in April 2022, is accessible through the MDMOOC website and WeChat platforms. Industry experts from various locations will lead the course, addressing key aspects of disease control and public health. Zhongchao remains committed to providing timely training for medical professionals in response to pandemic-related challenges.
Zhongchao Inc. (NASDAQ: ZCMD) reported a 94.6% decline in net income to $238,665 for the fiscal year 2021, down from $4.46 million in 2020. Revenues fell 9.4% to $16.30 million, primarily due to reduced income from medical training and education services. Gross profit also decreased by 20.5% to $9.44 million, leading to a gross margin decline of 8.1 percentage points. Operating expenses rose 32.2% to $9.76 million, driven by significantly increased general and administrative costs.
Zhongchao Inc. (NASDAQ: ZCMD) announced that its innovative patient management system has significantly improved the Duration of Therapy (DOT) by 40.4% for liver cancer patients. This improvement enhances drug efficiency and supports longer patient survival rates. The system aids nearly 20,000 patients in managing their treatment through education, follow-ups, and psychological support. With 400,000 new liver cancer cases reported in China in 2020, this advancement has the potential to notably impact patient outcomes and overall healthcare efficiency.
Zhongchao Inc. (NASDAQ: ZCMD) has launched the Hematology MDT Platform, an online training resource designed to enhance multidisciplinary treatment (MDT) skills for healthcare professionals. This platform facilitates real-time collaboration and problem-solving among physicians by providing access to expert guidance and training videos. As of August 2021, over 10,000 physicians have engaged with this platform, highlighting the growing demand for MDT in treating complex diseases like hematology within China. The company aims to expand this model across other medical areas to improve healthcare efficiency.
Zhongchao Inc. (NASDAQ: ZCMD) announced the launch of its Hematological Tumor Patient Care Center via its subsidiary, Shanghai Zhongxin Medical Technology. This initiative expands its services in tumor patient management to the out-of-hospital market, catering to nearly 10,000 hematological tumor patients. The Care Center provides comprehensive disease management, including patient education and personalized health assessments. With a projected rise in hematologic tumor cases in China, Zhongchao aims to enhance treatment experiences for patients through its innovative management services.